Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Alibaba Stock Jumps as Qwen 3.8-MAX AI Model Intensifies China's AI Race 
Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review 
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
Apple Restores Telegram to App Store After Content Policy Violation 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Palantir Stock Soars as AI Demand Drives Strong Q2 Earnings and Higher 2026 Outlook 
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says 
BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Vast Eyes Hong Kong IPO as Chinese AI Unicorn Gains Momentum 
Chery Invests $75 Million in KG Mobility to Expand Global Automotive Partnership 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
BOULDER, Colo., April 05, 2018 -- Biodesix®, Inc. will present new data confirming the ability of the company’s droplet digital PCR (ddPCR™)-based platform to reliably detect key mutations in blood for patients with lung cancer. The data will be presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2018, taking place April 14-18 in Chicago, Ill.
“Blood-based molecular testing overcomes multiple limitations associated with tissue-based testing and is becoming an increasingly important component of care for cancer patients,” said David Brunel, Biodesix CEO. “In this study, we used the highly sensitive ddPCR technology to detect multiple EGFR variants reliably and reproducibly, while maintaining the rapid turnaround time that is characteristic of our testing methodology.”
Presentation details:
Title: Highly multiplexed diagnostic test for the detection of extended EGFR del19 variants in patients with NSCLC (Poster #5573/5)
Session Date/Time: Wednesday, April 18, 8:00 a.m.-12:00 p.m. Central Time
Authors: Hestia Mellert, Ph. D., Leisa Jackson, Ph. D, Kristin Alexander, Amanda Weaver, Dianna Maar, Dawne Shelton, Gary Pestano, Ph. D.
Location: Exhibit Hall A, McCormick Place South (Level 3), Poster Section 26, Liquid Biopsy 5
AACR 2018 meeting abstracts are currently available on the AACR website. The Biodesix AACR 2018 abstract is also available on Biodesix.com. The poster will be available after April 18.
About Biodesix®
Biodesix is a molecular diagnostics company advancing the development of innovative, multi-omic blood tests in oncology to enable precision medicine. Biodesix discovers, develops and commercializes multivariate protein and genomic liquid biopsy tests, including the GeneStrat® and VeriStrat® tests, that deliver results within 72 hours. The company is changing the standard of care by providing physicians with diagnostic tests and with the Biodesix Lung Reflex™ testing strategy, for better therapeutic guidance, more accurate prognosis and enhanced disease monitoring to improve patient outcomes. At the forefront of personalized medicine, Biodesix is developing new tests to identify patients who may benefit from immunotherapies. In addition to developing novel diagnostics independently, the company partners with biotechnology and pharmaceutical companies to develop companion diagnostics for use with therapeutic agents.
For more information about Biodesix, please visit www.biodesix.com.
Contact: Rachel Biederman 720-214-5774 [email protected]
